DR
DRS
DRS What Leonardo DRS promised, and what happened
Guidance
What management said, and what became of it
29 of 32 judged targets kept · 49 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Quarterly adjusted EBITDA margin | Mid-12% range, comparable to Q1 | Mar 2026 | Adjusted EBITDA margin was 14%, up 240 basis points from the prior year. | Achieved |
| Full-year adjusted diluted EPS | $1.20 to $1.26 per share | Dec 2025 | We now expect adjusted diluted EPS of $1.34 to $1.39 a share. | Revised Up |
| Annual free cash flow seasonality and linearity | Similar quarterly trend to recent years with modest linearity improvements | Dec 2025 | We are seeing improved quarterly linearity relative to last year. Free cash flow was positive in the quarter, supported by higher profitability and greater working capital efficiency. | On Track |
The full ledger
Open Leonardo DRS’s full ledger
A free account opens 5 company ledgers a month. All 81 tracked commitments, with each call’s wording and source.
The rest of the ledger
Pro opens all 81 tracked commitments for Leonardo DRS
Above is what the last two calls moved. Pro adds every quarter's revision, the source quote behind each one, and the topics management has stopped answering.